How Will the Market React to AbCellera Biologics Inc (ABCL) Stock Getting a Bullish Rating

AbCellera Biologics Inc (ABCL) stock has gained 15.59% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

AbCellera Biologics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ABCL!

See Full ABCL Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With ABCL Stock Today?

AbCellera Biologics Inc (ABCL) stock is lower by -0.64% while the S&P 500 has risen 0.09% as of 10:26 AM on Monday, Nov 6. ABCL is lower by -$0.03 from the previous closing price of $4.70 on volume of 304,078 shares. Over the past year the S&P 500 has gained 14.59% while ABCL is lower by -61.12%. ABCL lost -$0.45 per share in the over the last 12 months. To screen for more stocks like AbCellera Biologics Inc click here.

More About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners. Click Here to get the full Stock Report for AbCellera Biologics Inc stock.